Moneycontrol
HomeNewsBusinessAs economy rebounds, 2021 will be 'much better' than 2020: Maruti Suzuki's RC Bhargava

As economy rebounds, 2021 will be 'much better' than 2020: Maruti Suzuki's RC Bhargava

Maruti Suzuki's domestic sales increased marginally to 1,44,219 units last month as against 1,43,686 units in November 2019.

December 02, 2020 / 19:09 IST
Story continues below Advertisement
Maruti Suzuki India | Company would re-start production of vehicles at its Manesar plant from May 12. (Image: Moneycontrol)

With the economic activities slowly getting back on track after COVID-19 lockdown, India’s biggest carmaker Maruti Suzuki is expecting 2021 to be “much better” than 2020.

The local unit of Japan’s Suzuki Motor Corp. had reported a 1.7 percent increase in sales to 1,53,223 units in November. It had stated in its statement that it sold 1,50,630 units in November last year. Maruti Suzuki's domestic sales increased marginally to 1,44,219 units last month as against 1,43,686 units in November 2019.

Story continues below Advertisement

Maruti Suzuki sales increase 1.7% to 1,53,223 units in November

With promising figures and economy rebounding, Maruti Suzuki India Ltd.'s Chairman RC Bhargava expected that the retail sales in December to be “pretty good”. He cited the reasons as pending orders with its dealerships and sustained rate of enquiries even after the festive season.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show